InvestSMART

Paradigm Biopharmaceuticals Limited (ASX:PAR)

ALERT: Price-sensitive ASX Announcement for PAR
Current share price for PAR : $0.180 0.005 (2.86%)+
Announcement
Release
13 Jul 2026 1:14PM
Price at Release
$0.175
Full Release
download
Summary
Paradigm Biopharmaceuticals Ltd. has completed the drawdown of Tranche 4 valued at US$3 million (approximately A$4.6 million) under its US$27 million (A$41.2 million) Convertible Note Facility with Obsidian Global Partners, LLC. This financial maneuver provides additional working capital to further support the global Phase 3 clinical trial of injectable pentosan polysulfate sodium (iPPS) for treating knee osteoarthritis. Following previous drawdowns, the company has successfully enrolled 538 participants and is progressing with dosing and follow-up activities across global sites. The drawdown aligns with ongoing treatment, follow-up assessments, database management, regulatory activities, and clinical operations. Approximately US$7 million remains available under the facility, ensuring financial flexibility for Phase 3 execution and commercial readiness. Paradigm remains disciplined in capital management to achieve key milestones, including interim analysis and primary endpoint readout.
Key Points
  • Completion of Tranche 4 drawdown valued at US$3 million.
  • Support for Phase 3 clinical trial of iPPS for knee osteoarthritis.
  • 538 participants enrolled in the study.
  • Continued dosing and follow-up activities.
  • US$7 million remains available under the facility.
  • Focus on disciplined capital management for key milestones.
  • Efforts towards commercial readiness activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.